Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An exploratory single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily for 12 weeks followed by 100 mg daily for 12 weeks in uterine adenomyosis

Next Previous
Trial Profile

An exploratory single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily for 12 weeks followed by 100 mg daily for 12 weeks in uterine adenomyosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linzagolix (Primary)
  • Indications Adenomyosis; Uterine diseases
  • Focus Therapeutic Use
  • Sponsors ObsEva

    • Most Recent Events

    • 20 Oct 2021 Primary endpoint (Change from baseline to week 24 in volume of the uterus with adenomyosis measured by Magnetic Resonance Imaging (MRI).) has been met according to an ObsEva media release
    • 20 Oct 2021 According to an ObsEva media release, data from this study were presented at the American Society for Reproductive Medicine (ASRM) 2021 Scientific Congress & Expo.
    • 20 Oct 2021 Results published in the ObsEva Media Release
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top